Gilead Sciences News

Brazil has rejected a patent request for an AIDS drug made by Gilead Sciences Inc.

Soon, Gilead Sciences of Foster City may be the last one still standing as an independent big-cap biotech company that has not been swallowed by a bigger pharma fish.

Patrick O'Brien, Investor Relations, 650-522-1936 Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the Thomas Weisel Partners Healthcare Conference in Boston.

Gilead Sciences Inc. plans to nearly double the office and R&D space at its Foster City headquarters as it adds 1,900 jobs there over 10 years.

Produced by the Foster City-based Gilead Sciences, the once-daily tablet Viread has been granted marketing approval for the treatment of chronic hepatitis B by the U.S. Food and Drug Administration, the ...

Gilead Sciences must defend charges that improper marketing encouraged demand for its HIV drug Viread.

Gilead Sciences Inc expects strong sales growth following recent data showing the superiority of its HIV drugs to a competing regimen, its president and chief operation officer told Reuters on Wednesday.

Main Category: Liver Disease / Hepatitis Also Included In: Regulatory Affairs / Drug Approvals Article Date: 12 Aug 2008 Gilead Sciences, Inc.

Gilead Sciences Inc. prepared to expand its reach further beyond AIDS drugs Monday after federal regulators approved the biotech drug maker's signature anti-HIV therapy as a hepatitis B treatment.

Drugs made by Gilead Sciences Inc . that have been shown to treat the AIDS virus will be tested in healthy people to see if they can prevent the lethal disease.

Gilead Sciences, Inc. and Merck & Co., Inc. announced that the companies have entered into an agreement through which Gilead will assume the lead role for the distribution of Atripla in 12 countries located ...

Data presented at an international HIV conference this month could boost sales of Gilead Sciences Inc.

Dr. Richard J. Whitley, a UAB pediatrics, microbiology, medicine and neurosurgery professor, has been named a director for Gilead Sciences Inc ., the Foster City, Calif.-based biopharmaceutical company said ...

Gilead Sciences Inc. and Merck & Co. Inc. said Friday they will collaborate on the distribution of HIV drug Atripla to 12 countries, primarily in Latin America and the Asia-Pacific region.

Gilead Sciences, Inc. announced today that Richard J. Whitley, MD has been appointed to the company's Board of Directors, bringing the number of Directors to 11.

Gilead Sciences Inc. started signing up patients for a Phase III trial of elvitegravir, a drug being studied as an HIV treatment.

Gilead Sciences Inc. started signing up patients for a Phase III trial of elvitegravir, a drug being studied as an HIV treatment.

Gilead Sciences this week announced initiation of a Phase III clinical trial of its experimental integrase inhibitor elvitegravir .

Main Category: HIV / AIDS Also Included In: Clinical Trials / Drug Trials Article Date: 24 Jul 2008 Gilead Sciences, Inc.

Shares of biotechnology company Gilead Sciences Inc. rose Wednesday after the company said it started a late-stage study of a new HIV treatment candidate.